Results 131 to 140 of about 95,952 (294)

Mechanism‐informed machine learning for individualized tacrolimus dose adjustment in the early post‐kidney transplant period

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Tacrolimus dosing in the early post‐kidney transplant period is challenging due to a narrow therapeutic index and substantial interindividual pharmacokinetic (PK) variability. This study aimed to develop and validate mechanism‐informed machine learning (ML) models to support individualized tacrolimus dosing during this critical period ...
Hui Yu   +4 more
wiley   +1 more source

Early clinical pharmacology evaluation of the novel anti‐inflammatory macrolide, glasmacinal (EP395): tolerability, pharmacokinetics and drug interactions

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aims This work assessed the pharmacokinetics (PK), safety and tolerability of glasmacinal (EP395, an oral anti‐inflammatory macrolide with negligible antimicrobial activity in development for COPD treatment) in two healthy participant trials: ‘first‐in‐human’ (FIH) and ‘drug–drug‐interaction’ (DDI).
Dave Singh   +5 more
wiley   +1 more source

A phase 1 evaluation of inhaled oxytocin: Physiologically‐based pharmacokinetic model informed dosing of a novel heat‐stable oxytocin delivery system

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim To develop and validate a physiologically‐based pharmacokinetic (PBPK) model enabling inhaled oxytocin dose selection for clinical evaluation. Subsequently, to conduct a phase 1 study investigating the pharmacokinetics and safety of selected doses of an optimized inhaled oxytocin product in healthy, non‐pregnant female participants.
Pete Lambert   +6 more
wiley   +1 more source

Quantitative prediction of intravenous drug interactions caused by cytochromes P450 inhibitors and inducers

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Background Aims Pharmacokinetic interaction studies typically focus on oral administration, but intravenous (IV) administration bypasses intestinal degradation and hepatic first‐pass metabolism, leading to distinct drug–drug interaction (DDI) magnitude. This study aimed to develop a predictive model for DDIs involving IV‐administered drugs.
Vianney Tuloup   +2 more
wiley   +1 more source

Endogenous melatonin partial metabolic clearance as a potential endogenous marker of CYP1A2 activity

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Cytochrome P450 1A2 (CYP1A2) exhibits substantial interindividual variability, necessitating appropriate phenotyping strategies for personalized pharmacotherapy. This study evaluated endogenous melatonin partial metabolic clearance (CLm(MEL)), calculated from urinary 6‐hydroxymelatonin (6‐O‐MEL) excretion and plasma melatonin (MEL) exposure, as a ...
Akitomo Yokokawa   +5 more
wiley   +1 more source

Dissolution Rates of Mangosteen (Garcinia mangostana L.) Pericarps Extract Granules in Synthetic Human Gastrointestinal Fluid [PDF]

open access: yes, 2014
Mangosteen (Garcinia mangostana L.) pericarps contain prenylated xanthone derivates, which exhibit some pharmacological activities, such as antiinflammatory, antihistamine, antibacterial, antivirus, antifungal, antioxidant, and antiulcerogenic.
Kumoro, A.C., Solikhati, A.
core  

Addressing Small Data Challenges in Biopharmaceutical Development and Manufacturing: A Mini Review of Multi‐Fidelity Techniques

open access: yesBiotechnology and Bioengineering, EarlyView.
ABSTRACT The growing demand for biopharmaceutical products reflects their effectiveness in medical treatments. However, developing new biopharmaceuticals remains a major bottleneck, often taking up to a decade before market approval. Machine learning (ML) models have the potential to accelerate this process, but their success depends on access to large
Mohammad Golzarijalal   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy